Australia Prostate Cancer Therapeutics Market Size & Outlook
Australia prostate cancer therapeutics market, 2018-2030 (US$M)
Related Markets
Australia prostate cancer therapeutics market highlights
- The Australia prostate cancer therapeutics market generated a revenue of USD 219.9 million in 2022 and is expected to reach USD 465.9 million by 2030.
- The Australia market is expected to grow at a CAGR of 9.8% from 2023 to 2030.
- In terms of segment, hormonal therapy was the largest revenue generating drug class in 2022.
- Hormonal Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
Prostate cancer therapeutics market data book summary
| Market revenue in 2022 | USD 219.9 million |
| Market revenue in 2030 | USD 465.9 million |
| Growth rate | 9.8% (CAGR from 2022 to 2030) |
| Largest segment | Hormonal therapy |
| Fastest growing segment | Hormonal Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Other Drug Class, Hormonal Therapy |
| Key market players worldwide | Johnson & Johnson, Astellas Pharma Inc, Eli Lilly and Co, Sanofi SA, Ipsen SA, Bayer AG, AstraZeneca PLC, Bausch Health Companies Inc, Merck & Co Inc, Pfizer Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 1.9% of the global prostate cancer therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China prostate cancer therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,452.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Therapeutics Market Scope
Prostate Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia prostate cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer therapeutics market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 88.4% in 2022. Horizon Databook has segmented the Australia prostate cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy, other drug class, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Australia prostate cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia prostate cancer therapeutics market databook
-
Our clientele includes a mix of prostate cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia prostate cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia prostate cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia prostate cancer therapeutics market size, by drug class, 2018-2030 (US$M)
Australia Prostate Cancer Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
